Valuation: United Therapeutics Corporation

Market Cap 23.13B 20.25B 18.7B 17.46B 32.87B 2,187B 33.61B 225B 86.86B 1,079B 86.86B 84.96B 3,746B P/E 2026 *
20.1x
P/E 2027 * 17.2x
Enterprise Value 20.48B 17.94B 16.56B 15.46B 29.11B 1,937B 29.77B 199B 76.92B 955B 76.93B 75.24B 3,317B EV / Sales 2026 *
6.31x
EV / Sales 2027 * 5.2x
Free-Float
53.71%
Yield 2026 *
-
Yield 2027 * -
1 day+0.42%
1 week+1.23%
Current month-2.14%
1 month-2.14%
3 months+4.23%
6 months+8.36%
Current year+11.84%
1 week 535.44
Extreme 535.44
555.32
1 month 532.59
Extreme 532.59
560.97
Current year 455.63
Extreme 455.63
609.35
1 year 272.12
Extreme 272.12
609.35
3 years 208.62
Extreme 208.6249
609.35
5 years 158.38
Extreme 158.38
609.35
10 years 74.31
Extreme 74.31
609.35
Manager TitleAgeSince
Chief Executive Officer 71 1996-06-25
President 54 2016-06-25
Director of Finance/CFO 58 2015-03-12
Director TitleAgeSince
Director/Board Member 78 2001-12-31
Chairman 71 1996-06-25
Director/Board Member 92 2001-12-31
Date Insider Type Main position Quantity % Market Cap.
06-24Fiscal year

Chief Executive Officer

28,500 0.0671%
06-23Fiscal year

Chief Executive Officer

28,500 0.0671%
06-22Fiscal year

Chief Executive Officer

28,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%+1.23%+91.69%+147.93% 23.13B
+1.81%+11.60%+58.61%+164.79% 1,097B
+1.51%+11.77%+69.61%+57.53% 622B
+0.38%+10.56%+39.49%+90.88% 449B
-0.90%+6.34%+29.51%+24.01% 334B
+1.01%+6.74%+43.34%+28.64% 294B
+1.08%+3.40%+32.70%+41.80% 286B
+1.29%+3.70%-27.40%-41.94% 213B
+0.62%+4.59%+30.10%+63.03% 195B
-1.21%+1.17%+14.15%+66.20% 157B
Average +0.10%+6.23%+38.18%+64.29% 366.99B
Weighted average by Cap. +0.05%+8.67%+44.05%+82.53%

Financials

2026 *2027 *
Net sales 3.25B 2.84B 2.63B 2.45B 4.61B 307B 4.72B 31.59B 12.19B 151B 12.2B 11.93B 526B 3.7B 3.24B 2.99B 2.8B 5.26B 350B 5.38B 36.03B 13.91B 173B 13.91B 13.61B 600B
Net income 1.26B 1.11B 1.02B 953M 1.79B 119B 1.83B 12.28B 4.74B 58.87B 4.74B 4.64B 204B 1.48B 1.3B 1.2B 1.12B 2.1B 140B 2.15B 14.4B 5.56B 69.07B 5.56B 5.44B 240B
Net Debt -2.65B -2.32B -2.14B -2B -3.76B -250B -3.85B -25.74B -9.94B -123B -9.94B -9.72B -428B -3.86B -3.38B -3.12B -2.92B -5.49B -365B -5.62B -37.58B -14.51B -180B -14.51B -14.19B -626B
Logo United Therapeutics Corporation
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Employees
1,400
Date Price Change Volume
26-06-29 US$544.92 +0.42% 420,258
26-06-26 US$542.66 -0.13% 1,022,244
26-06-25 US$543.39 -1.18% 285,355
26-06-24 US$549.90 +1.02% 377,592
26-06-23 US$544.33 +1.12% 1,081,315
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
544.92USD
Average target price
665.23USD
Spread / Average Target
+22.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UTHR Stock